This afternoon we watched Centene drop -2.8% to a price of $54.88 per share. The Large-Cap Medical Specialities company is now trading -28.65% below its average target price of $76.91. Analysts have set target prices ranging from $61.0 to $92.0 per share for Centene, and have given the stock an average rating of buy.
Centene's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 2.5%. The stock's short ratio is 1.98. The company's insiders own 0.46% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Another number to watch is the company's rate of institutional share ownership, which now stands at 100.0%. In conclusion, we believe there is mixed market sentiment regarding Centene.
Institutions Invested in Centene
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-03-31 | Vanguard Group Inc | 12% | 57,526,899 | $3,156,788,582 |
| 2025-03-31 | Blackrock Inc. | 9% | 45,171,577 | $2,478,790,287 |
| 2025-03-31 | FMR, LLC | 5% | 26,627,525 | $1,461,185,434 |
| 2024-12-31 | NORGES BANK | 5% | 25,357,664 | $1,391,501,812 |
| 2025-03-31 | State Street Corporation | 5% | 22,672,327 | $1,244,143,944 |
| 2025-03-31 | Harris Associates L.P. | 4% | 21,135,939 | $1,159,834,652 |
| 2025-03-31 | Capital World Investors | 3% | 14,909,941 | $818,183,012 |
| 2025-03-31 | Geode Capital Management, LLC | 3% | 12,929,002 | $709,478,984 |
| 2025-03-31 | Invesco Ltd. | 2% | 11,091,964 | $608,671,524 |
| 2025-03-31 | AQR Capital Management, LLC | 2% | 11,049,494 | $606,340,983 |
